Mack Flinspach

Mack Flinspach has a diverse work experience spanning various companies and roles within the field of protein chemistry, structural biology, and biologics research.

Mack'smost recent position was as the Executive Director of Protein Chemistry and Structural Biology at Velia, where they have been since 2022. Prior to that, they worked as the Executive Director of Structural Biology at Odyssey Therapeutics from 2021 to 2022.

From 2018 to 2021, Mack served in roles at Takeda, starting as an Associate Director of Structural Biology and later becoming the Director of Structural Biology. In these positions, they led a global team, managed budgets and timelines, and facilitated structure-based drug design for multiple projects concurrently.

Before their time at Takeda, Mack was the Director of Protein Engineering at Metacrine, Inc. from 2015 to 2018. Mack led the FGF1 insulin-sensitizer program and played a key role in establishing the Protein Engineering team for the start-up company.

Prior to that, Mack held various positions at The Janssen Pharmaceutical Companies of Johnson & Johnson from 2008 to 2015. Mack served as a Principal Scientist, Lead Peptide Engineer for the Aranea internal venture, and later as a Senior Scientist in Biologics Research. Mack also worked as a Scientist in Biologics Research at J&J.

Earlier in their career, Mack worked as a Scientist in Structural Biology at Senomyx and as a Post-doc at the Salk Institute for Biological Studies and GNF.

Throughout their career, Mack has demonstrated strong leadership skills, the ability to manage teams and projects, and a commitment to driving research and innovation in the field of biotechnology.

Mack Flinspach completed their Bachelor's Degree in Biology at California State University-San Bernardino from 1995 to 1999. Mack then pursued further education at UC Irvine, where they obtained their Ph.D in Biological Sciences from the Department of Molecular Biology and Biochemistry between 1999 and 2004.